CURIS INC: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei CURIS INC listata cu simbolul US.CRIS ==Descriere companie== Curis, Inc. (www.curis.com) is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with n...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Curis, Inc. (www.curis.com) is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program. | Curis, Inc. (www.curis.com) is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-[[arm]] dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||